CTMX
CytomX Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- CytomX Therapeutics received FDA Fast Track designation for Varseta-M in relapsed or refractory metastatic colorectal cancerAug 27, 2026
- CytomX Therapeutics provides update on CX-2051 Phase 1 studyAug 13, 2025
- CytomX Therapeutics announces first patient dosed in the combination arm of Phase 1 study of CX-801 plus KEYTRUDA® (pembrolizumab) in metastatic melanoma patients.May 19, 2025
- CytomX announces positive interim data from Phase 1 dose escalation study of EpCAM antibody drug conjugate (CX-2051) in patients with advanced colorectal cancer.May 12, 2025